贝瑞基因收盘上涨3.71%，最新市净率2.21，总市值41.47亿元

Group 1 - The core viewpoint of the article highlights the performance and market position of Berry Genomics, noting its recent stock price increase and market capitalization [1] - As of April 9, Berry Genomics closed at 11.73 yuan, up 3.71%, with a latest price-to-book ratio of 2.21 and a total market value of 4.147 billion yuan [1] - The company experienced a net outflow of main funds amounting to 21.2337 million yuan on April 9, with a total outflow of 64.5244 million yuan over the past five days [1] Group 2 - Berry Genomics specializes in gene testing services and related equipment and reagent sales based on high-throughput sequencing technology [1] - The company offers a comprehensive solution of "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The company has developed the cSMART liquid biopsy technology with a resolution of ten thousand levels, securing its leading position in oncology through domestic and international patents [1] Group 3 - The latest financial results for the third quarter of 2024 show that the company achieved an operating income of 0.823 billion yuan, a year-on-year decrease of 4.96%, and a net profit of 10.3855 million yuan, a year-on-year increase of 107.70%, with a gross profit margin of 50.61% [1] - In comparison to industry averages, Berry Genomics has a TTM PE of -14.71 and a static PE of -9.71, with a price-to-book ratio of 2.21, while the industry average PE is 45.15 [2] - The industry median price-to-book ratio is 2.24, indicating that Berry Genomics is positioned competitively within the sector [2]